Trial site
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York 10021, United StatesNot linked to an institution yet
- 19running trials
- 8closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 115 trials
- Phase 1/25 trials
- Phase 24 trials
- Phase 33 trials
- Phase 2/31 trial
- Status
- Recruiting12 trials
- Active, not recruiting6 trials
- Completed6 trials
- Terminated2 trials
- Not yet recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Eli Lilly and Company9 trials
- C4 Therapeutics, Inc.2 trials
- Coherus Oncology, Inc.2 trials
- Daiichi Sankyo2 trials
- Aadi Bioscience, Inc.1 trial
- and 12 more
Running trials
Not yet recruiting
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144· Phase 1· Coherus Oncology, Inc.· Source
Contact: Amin Yaqubie
Active, not recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985· Phase 2· Coherus Oncology, Inc.· Source
Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
NCT06644755· Phase 1· Daiichi Sankyo· Source
Active, not recruiting
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515· Phase 1· Eli Lilly and Company· Source
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472· Phase 1· Eli Lilly and Company· Source
Contact: Chrisann Kyi (principal investigator)
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Sherry Shen
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812· Phase 1/2· Debiopharm International SA· Source
Contact: Debiopharm International S.A
Recruiting
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
NCT05826535· Phase 1/2· Lyell Immunopharma, Inc.· Source
Contact: Stephen Simko, MD
Active, not recruiting
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
NCT04485949· Phase 2· Imvax· Source
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371· Phase 1/2· BicycleTx Limited· Source
Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933· Phase 1· Inhibrx Biosciences, Inc· Source
Contact: Care Advisors
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT05561751· Phase 2· GPCR Therapeutics, Inc.· Source
Completed
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585· Phase 1· C4 Therapeutics, Inc.· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Terminated
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
NCT05355753· Phase 1· C4 Therapeutics, Inc.· Source
Completed
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source
Completed
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516· Phase 1· Syndax Pharmaceuticals· Source
Completed
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Ipsen· Source
Report an error